MITO: Stealth BioTherapeutics' Treatments Gain Momentum

By Brad Sorensen, CFA

NASDAQ:MITO

READ THE FULL MITO RESEARCH REPORT

Stealth BioTherapeutics MITO is clinical stage biopharmaceutical company that is attempting to repair mitochondria to treat previously untreatable conditions. Stealth BioTherapeutics announced that its signature treatment, elamipretide, was awarded Orphan Drug Designation for the treatment of Friedreich's Ataxia. The company also announce positive results from its preclinical trial of SBT-272 in a mouse model of Huntington's disease.

Friedrich's ataxia, the most common form of ataxia, affects about 1 in 40,000 people in the United States. Friedrich's ataxia is an inherited, genetic disease that damages the spinal cord, peripheral nerves and the cerebellum portion of the brain. The condition typically develops in children and gradually grows worse over time. Friedrich's is caused by a genetic defect in the gene labeled FXN, which carries the genetic code for a protein called frataxin. In preclinical studies, elamipretide has been shown to improved mitochondrial structure and function as well as increasing mature frataxin levels in Friedrich's patient lymphoblasts. As a result of these positive developments, the researcher involved in this study has submitted a Phase 2a clinical trial to the FDA and is currently waiting for Institutional Review Board approval. Stealth is supporting the study in the assessment of the impact of elamipretide in a cohort of patients affected by cardiomyopathy and/or visual decline associated with Friedrich's. As noted above, and we believe this to be a fairly significant development, Stealth has been granted Orphan Drug Designation for elamipretide for the treatment of Friedrich's ataxia, which provides various benefits including the potential for seven years of market exclusivity after approval.

Elamipretide is not the only compound that Stealth is developing. In fact, although it's early in the process, early indications from the compound known as SBT-272, in our view, may end up being the most consequential development from Stealth out of the current potential treatments—both in terms of impact on patients and the commercialization possibilities. Stealth's primary objective in designing SBT-272 was to increase brain exposure compared to elamipretide due to the potential that mitochondrial may be beneficial in neurological disorders such as amyotrophic lateral sclerosis (ALS), Parkinson's, Huntington's and Alzheimer's.

Preclinical data, according to Stealth, showed that SBT-272 demonstrated a three times greater concentration of the compound in the brains of rats compared to elamipretide and 25 times greater area under the concentration-time curve—both of which suggest that SBT-272 has both higher brain exposure and greater residence time.

Stealth also recently announced at the Mitochondrial Biochemistry in Health and Disease Symposium that preclinical trials of SBT-272 produced data that demonstrated behavioral and metabolic improvements in a mouse model of Huntington's disease. In the study, mice were treated for up to 8 weeks with daily SBT-272 and displayed significantly improved motor function compared to vehicle-treated mice. SBT-272-treated mice also showed improved metabolism in multiple brain regions of the diseased animals, assessed in vivo using PET imaging.

Stealth is at the beginning stages of moving SBT-272 through the approval process with the Phase I trial, with the company announcing in March 2022 the dosing of the first subject, and we will be watching the developments of this compound carefully. We continue to view MITO as a speculative investment in an exciting industry that we believe is worth of a close look by investors who have a slightly higher risk tolerance. The runway is fairly long and potentially bumpy, but the potential for a pretty substantial take off also exists.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.